In this session, Fauna Bio’s CEO/Founder will share the journey of how the company utilized its Convergence™ AI platform to forge a groundbreaking partnership with Eli Lilly. Attendees will learn how Fauna Bio’s approach to identifying novel obesity targets based on animal genomics is opening new frontiers in biotech innovation.
• Strategic Partnering: How Fauna Bio identified and approached Lilly as a collaborator to align their platform technology with a strategic pharma need.
• Innovative Science Meets Big Pharma: How the Convergence™ AI platform, inspired by hibernation biology, attracted attention from one of the leading players in obesity treatment.
• Lessons in Deal Structuring: A behind-the-scenes look at securing a deal with big pharma.
